**Biomarkers of Systemic Treatment Outcomes in Psoriasis**

**BASELINE CRF**

**For patients on PSORTD enrolling onto B-STOP**

**Version 10**

---

**B-STOP ID:**

**PSORTD ID:**

**BADBIR ID:**

**Initials:**

**D.O.B:**

**Gender:**

- Male
- Female

**ETHNICITY (Please circle):**

- White
- Black or Black British
- Asian or Asian British
- Chinese
- Mixed background
- Other

If Mixed Background / Other, please specify:

---

### 1. PATIENT CONSENT

1a. Is the patient registered on PSORTD?  
   - YES
   - NO (Not eligible for recruitment)

1b. Is the patient due to enrol onto BADBIR or already on BADBIR?  
   - YES
   - NO

1c. Has the patient given written Informed Consent for B-STOP?  
   - YES
   - NO (Not eligible for recruitment)

1d. Date of Consent to B-STOP:

   - dd/mm/yyyy

1e. Does this patient consent to Psoriasis Biobank? (see Q.9 on Consent Form)  
   - YES
   - NO

1e. Does this patient consent to being recalled? (see Q.11 on Consent Form)  
   - YES
   - NO

---

### 2. TREATMENT DETAILS

2a. Please tick the boxes and complete details for all the patient’s current or expected Psoriasis treatments:

#### Biologic drugs

<table>
<thead>
<tr>
<th>Drug name</th>
<th>Dose (mg)</th>
<th>Frequency</th>
<th>Date started</th>
<th>Date of dose</th>
<th>Time of dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adalimumab</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ustekinumab</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other - write name</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Conventional and Small Molecule drugs

<table>
<thead>
<tr>
<th>Drug name</th>
<th>Dose (mg)</th>
<th>Frequency</th>
<th>Date started</th>
<th>Date of most recent dose</th>
<th>Time of dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methotrexate</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other - write name</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

2b. If the patient is taking Methotrexate, is this being taken subcutaneously (by injection)?  
   - YES
   - NO

---

### 3. CURRENT STATUS - Please indicate the current disease severity

3a. PASI  
   -  
3b. DLQI  
   - Date of assessment:

   - dd/mm/yyyy

3c. Psoriasis Global Assessment

- Severe
- Moderate to Severe
- Moderate
- Mild
- Almost Clear
- Clear

---

*Version 10, 23/08/2019*
4. SAMPLE COLLECTION

**4a FOR ALL PATIENTS - DNA SAMPLE**
- 2 x 6ml PINK TOP tube
- Freeze within 4 hours (or post with methotrexate sample if collected)

**4b FOR PATIENTS ON OR STARTING BIOLOGIC THERAPY**
- 2 x 5ml YELLOW TOP tube
  - Ideally collect at trough (before dosing)
  - Spin in centrifuge at 1000g for 10 minutes, pipette into micro-tube
  - Freeze within 4 hours

**4c FOR PATIENTS ON OR STARTING CONVENTIONAL THERAPY**
- 1 x 5ml YELLOW TOP tube
  - Process as 5b above

**4d FOR PATIENTS ON METHOTREXATE THERAPY**
- 1 x 4ml PURPLE TOP tube
  - Not required before treatment has commenced
  - DO NOT FREEZE, place in blue Royal Mail Safebox and mail to Guy’s Hospital

**4e FOR PATIENTS SWITCHING OR STARTING A NEW TREATMENT**
- 1 x BLUE TEMPUS tube
  - Collect before treatment start and then 4 and 12 weeks after treatment starts
  - Ideally collect at trough (before dosing)
  - Shake vigorously for 10 seconds immediately following collection

Please tick boxes to confirm collection

Clinician’s Name: ____________________________________________

Clinician’s Signature: ________________________________________  Date:  ____/____/____